132 related articles for article (PubMed ID: 17981532)
1. Structure and function of the papillomavirus E6 protein and its interacting proteins.
Liu Y; Baleja JD
Front Biosci; 2008 Jan; 13():121-34. PubMed ID: 17981532
[TBL] [Abstract][Full Text] [Related]
2. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
3. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background.
Massimi P; Shai A; Lambert P; Banks L
Oncogene; 2008 Mar; 27(12):1800-4. PubMed ID: 17934525
[TBL] [Abstract][Full Text] [Related]
4. Association of papillomavirus E6 proteins with either MAML1 or E6AP clusters E6 proteins by structure, function, and evolutionary relatedness.
Brimer N; Drews CM; Vande Pol SB
PLoS Pathog; 2017 Dec; 13(12):e1006781. PubMed ID: 29281732
[TBL] [Abstract][Full Text] [Related]
5. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
[TBL] [Abstract][Full Text] [Related]
6. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity.
Drews CM; Brimer N; Vande Pol SB
PLoS Pathog; 2020 Jan; 16(1):e1008295. PubMed ID: 31971989
[TBL] [Abstract][Full Text] [Related]
7. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein.
Zhang Y; Dasgupta J; Ma RZ; Banks L; Thomas M; Chen XS
J Virol; 2007 Apr; 81(7):3618-26. PubMed ID: 17267502
[TBL] [Abstract][Full Text] [Related]
8. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.
Lagrange M; Charbonnier S; Orfanoudakis G; Robinson P; Zanier K; Masson M; Lutz Y; Trave G; Weiss E; Deryckere F
J Gen Virol; 2005 Apr; 86(Pt 4):1001-1007. PubMed ID: 15784893
[TBL] [Abstract][Full Text] [Related]
9. Papillomavirus E6 PDZ interactions can be replaced by repression of p53 to promote episomal human papillomavirus genome maintenance.
Brimer N; Vande Pol SB
J Virol; 2014 Mar; 88(5):3027-30. PubMed ID: 24352452
[TBL] [Abstract][Full Text] [Related]
10. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6.
Matsumoto Y; Nakagawa S; Yano T; Takizawa S; Nagasaka K; Nakagawa K; Minaguchi T; Wada O; Ooishi H; Matsumoto K; Yasugi T; Kanda T; Huibregtse JM; Taketani Y
J Med Virol; 2006 Apr; 78(4):501-7. PubMed ID: 16482544
[TBL] [Abstract][Full Text] [Related]
11. Design of a PDZbody, a bivalent binder of the E6 protein from human papillomavirus.
Karlsson OA; Ramirez J; Öberg D; Malmqvist T; Engström Å; Friberg M; Chi CN; Widersten M; Travé G; Nilsson MT; Jemth P
Sci Rep; 2015 Mar; 5():9382. PubMed ID: 25797137
[TBL] [Abstract][Full Text] [Related]
12. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus type 16 E6 protein interacts with cystic fibrosis transmembrane regulator-associated ligand and promotes E6-associated protein-mediated ubiquitination and proteasomal degradation.
Jeong KW; Kim HZ; Kim S; Kim YS; Choe J
Oncogene; 2007 Jan; 26(4):487-99. PubMed ID: 16878151
[TBL] [Abstract][Full Text] [Related]
14. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase.
Kelley ML; Keiger KE; Lee CJ; Huibregtse JM
J Virol; 2005 Mar; 79(6):3737-47. PubMed ID: 15731267
[TBL] [Abstract][Full Text] [Related]
15. Determinants of stability for the E6 protein of papillomavirus type 16.
Liu Y; Cherry JJ; Dineen JV; Androphy EJ; Baleja JD
J Mol Biol; 2009 Mar; 386(4):1123-37. PubMed ID: 19244625
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase.
Kao WH; Beaudenon SL; Talis AL; Huibregtse JM; Howley PM
J Virol; 2000 Jul; 74(14):6408-17. PubMed ID: 10864652
[TBL] [Abstract][Full Text] [Related]
17. Structural and biochemical analysis of the PTPN4 PDZ domain bound to the C-terminal tail of the human papillomavirus E6 oncoprotein.
Lee HS; Yun HY; Lee EW; Shin HC; Kim SJ; Ku B
J Microbiol; 2022 Apr; 60(4):395-401. PubMed ID: 35089587
[TBL] [Abstract][Full Text] [Related]
18. Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins.
Jing M; Bohl J; Brimer N; Kinter M; Vande Pol SB
J Virol; 2007 Mar; 81(5):2231-9. PubMed ID: 17166906
[TBL] [Abstract][Full Text] [Related]
19. Development of screening systems for drugs against human papillomavirus-associated cervical cancer: based on E6-E6AP binding.
Cho Y; Cho C; Joung O; Lee K; Park S; Yoon D
Antiviral Res; 2000 Sep; 47(3):199-206. PubMed ID: 10974372
[TBL] [Abstract][Full Text] [Related]
20. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
